Business context and reporting period
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) filed this Form 8-K on October 6, 2026, reporting that its board adopted a new Section 382 rights agreement. It replaces a prior rights agreement that expires October 18, 2026. The new agreement is intended to help preserve the company’s net operating loss carryforwards (NOLs) and other tax benefits.
Key financial information
This 8-K reports no revenue, earnings, cash flow, margin, debt, or liquidity figures. It provides no new financial results or guidance.
Material changes and agreement terms
- One preferred stock purchase right is to be issued for each common share outstanding on the October 13, 2026 record date. Each right initially permits its holder to buy one one-thousandth of a Series B preferred share for $10, subject to adjustment.
- Rights generally become exercisable after the company learns that a person or group beneficially owns 4.99% or more of outstanding common stock, or if the board sets a trigger after a qualifying tender or exchange offer. Rights are initially non-exercisable.
- Persons already at or above 4.99% on October 6, 2026 are generally grandfathered, but may not exceed their recorded ownership percentage by 0.5 percentage points without triggering the agreement.
- After a trigger, rights held by an acquiring person become void; other holders may receive preferred stock with a market value tied to twice the purchase price. The agreement also includes provisions for certain acquisitions and permits the board to exchange or, before an acquiring-person trigger, redeem rights for $0.0001 per right.
- The rights expire on the earliest of October 6, 2036, expiration or exhaustion of the relevant tax benefits, or earlier redemption or exchange.
Management commentary, risks, and unusual items
The company says it has experienced and continues to experience substantial operating losses and believes its NOLs and other tax benefits could be a substantial asset. It warns that an ownership change under Section 382 of the Internal Revenue Code could substantially limit their use. The rights agreement is intended to deter ownership changes, but its thresholds and dilution provisions may also affect shareholders’ ability to acquire shares and could complicate a change in control. The filing gives no quantified estimate of the tax benefits or potential limitation.
The filing contains standard forward-looking-statement cautions and refers investors to the company’s other SEC filings for risk factors. It states that the board adopted an amended and restated Series B Preferred Stock certificate of designation, effective October 6, 2026.
Important facts for investors to verify
- Review Exhibits 3.1 and 4.1 for the full rights agreement, preferred-stock terms, definitions, exceptions, and adjustment mechanics.
- Confirm the October 13, 2026 record date and the applicable ownership thresholds, including treatment of existing large holders.
- Consult the company’s latest financial statements and tax disclosures for the amount, nature, and potential usability of its NOLs and other tax benefits.
- Note that the filing refers once to the replaced agreement as a “Section 182” agreement, while otherwise describing the agreement and tax issue under Section 382.
- Exhibit 4.1 identifies the agreement parties as Sonoma Pharmaceuticals, Inc. and Computershare Inc., but the exhibit description names “Oculus Innovative Sciences, Inc.”; review the filed exhibit for clarification.